ENHANCEMENT OF THE CELLULAR IMMUNE RESPONSE

摘要

DTH-Effector T-cells expressing the CD5 and not the CD8 phenotype are primed with an antigen containing a specific tumor-associated carbohydrate determinant and are used to enhance the cellular immune response. Tumors have been inhibited by DTH-Effector cells expressing the CD5 and not the CD8 phenotype cells primed with such antigen containing a tumor-associated specific carbohydrate determinant, e.g., with epiglycanin and with synthetic T and Tn antigens. Either the DTH-Effector cells expressing the CD5 and not the CD8 phenotype, or those specific tumor-asso-ciated carbohydrate antigens directly, may be used for tumor prophylaxis and therapy.